Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C.

摘要

We read with great interest the letter by Neumann et al. [1] on the effect of Silibinin in preventing graft infection in a patient with cirrhosis due to chronic hepatitis C (HCV). We obtained the same result in a patient treated with intravenous (i.v.) Silibinin mono-therapy (Legalon SIL~R, Rottapharm-Madaus). In 1994, the 46-year-old male patient with beta-thalassemia was first diagnosed for HCV with mixed genotype 1a/4. Both genotypes were also present upon starting silibinin treatment and on the day of OLTx. In 1998, he was treated with 5 MU inter-feron three times a week and weight based ribavirin. Treatment was stopped due to failure to clear the virus after 24 weeks of treatment.